120 related articles for article (PubMed ID: 29684526)
1. Targeted-gene silencing of BRAF to interrupt BRAF/MEK/ERK pathway synergized photothermal therapeutics for melanoma using a novel FA-GNR-siBRAF nanosystem.
Zhang Y; Zhan X; Peng S; Cai Y; Zhang YS; Liu Y; Wang Z; Yu Y; Wang Y; Shi Q; Zeng X; Yuan K; Zhou N; Joshi R; Zhang M; Zhang Z; Min W
Nanomedicine; 2018 Jul; 14(5):1679-1693. PubMed ID: 29684526
[TBL] [Abstract][Full Text] [Related]
2. Targeted Gene Silencing BRAF Synergized Photothermal Effect Inhibits Hepatoma Cell Growth Using New GAL-GNR-siBRAF Nanosystem.
Liu Y; Tan M; Zhang Y; Huang W; Min L; Peng S; Yuan K; Qiu L; Min W
Nanoscale Res Lett; 2020 May; 15(1):116. PubMed ID: 32449085
[TBL] [Abstract][Full Text] [Related]
3. Coated microneedles mediated intradermal delivery of octaarginine/BRAF siRNA nanocomplexes for anti-melanoma treatment.
Ruan W; Zhai Y; Yu K; Wu C; Xu Y
Int J Pharm; 2018 Dec; 553(1-2):298-309. PubMed ID: 30347273
[TBL] [Abstract][Full Text] [Related]
4. Biomineralized Polydopamine Nanoparticle-Based Sodium Alginate Hydrogels for Delivery of Anti-serine/Threonine Protein Kinase B-Rapidly Accelerated Fibrosarcoma siRNA for Metastatic Melanoma Therapy.
Lu J; Song J; Zhang P; Huang Y; Lu X; Dai H; Xi J
ACS Nano; 2023 Sep; 17(18):18318-18331. PubMed ID: 37690074
[TBL] [Abstract][Full Text] [Related]
5. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
6. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
7. Non-covalently functionalized single-walled carbon nanotube for topical siRNA delivery into melanoma.
Siu KS; Chen D; Zheng X; Zhang X; Johnston N; Liu Y; Yuan K; Koropatnick J; Gillies ER; Min WP
Biomaterials; 2014 Mar; 35(10):3435-42. PubMed ID: 24424208
[TBL] [Abstract][Full Text] [Related]
8. Tetrahedral Framework Nucleic Acids Loaded with Aptamer AS1411 for siRNA Delivery and Gene Silencing in Malignant Melanoma.
Xiao D; Li Y; Tian T; Zhang T; Shi S; Lu B; Gao Y; Qin X; Zhang M; Wei W; Lin Y
ACS Appl Mater Interfaces; 2021 Feb; 13(5):6109-6118. PubMed ID: 33497198
[TBL] [Abstract][Full Text] [Related]
9. Dendritic Cell-Derived Exosomes Driven Drug Co-Delivery Biomimetic Nanosystem for Effective Combination of Malignant Melanoma Immunotherapy and Gene Therapy.
Lin J; Huang N; Li M; Zheng M; Wang Z; Zhang X; Gao H; Lao Y; Zhang J; Ding B
Drug Des Devel Ther; 2023; 17():2087-2106. PubMed ID: 37489176
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
11. Targeted gold nanorods combined with low-intensity nsPEFs enhance antimelanoma efficacy in vitro.
Mi Y; Liu Q; Li P; Xu J; Yang Q; Tang J
Nanotechnology; 2020 Aug; 31(35):355102. PubMed ID: 32396891
[TBL] [Abstract][Full Text] [Related]
12. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.
Park SJ; Hong SW; Moon JH; Jin DH; Kim JS; Lee CK; Kim KP; Hong YS; Choi EK; Lee JS; Lee JL; Kim TW
Am J Med Sci; 2013 Dec; 346(6):494-8. PubMed ID: 24051957
[TBL] [Abstract][Full Text] [Related]
13. A novel multifunctional gold nanorod-mediated and tumor-targeted gene silencing of GPC-3 synergizes photothermal therapy for liver cancer.
Liu Y; Tan M; Fang C; Chen X; Liu H; Feng Y; Zhang Y; Min W
Nanotechnology; 2021 Apr; 32(17):175101. PubMed ID: 33445163
[TBL] [Abstract][Full Text] [Related]
14. Gold-nanorods-siRNA nanoplex for improved photothermal therapy by gene silencing.
Wang BK; Yu XF; Wang JH; Li ZB; Li PH; Wang H; Song L; Chu PK; Li C
Biomaterials; 2016 Feb; 78():27-39. PubMed ID: 26646625
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional gold nanorods in low-temperature photothermal interactions for combined tumor starvation and RNA interference therapy.
Fan R; Chen C; Hu J; Mu M; Chuan D; Chen Z; Guo G; Xu J
Acta Biomater; 2023 Mar; 159():324-337. PubMed ID: 36706851
[TBL] [Abstract][Full Text] [Related]
16. Chitosan layered gold nanorods as synergistic therapeutics for photothermal ablation and gene silencing in triple-negative breast cancer.
Yang Z; Liu T; Xie Y; Sun Z; Liu H; Lin J; Liu C; Mao ZW; Nie S
Acta Biomater; 2015 Oct; 25():194-204. PubMed ID: 26193000
[TBL] [Abstract][Full Text] [Related]
17. Tumor-Targeted Gene Silencing IDO Synergizes PTT-Induced Apoptosis and Enhances Anti-tumor Immunity.
Zhang Y; Feng Y; Huang Y; Wang Y; Qiu L; Liu Y; Peng S; Li R; Kuang N; Shi Q; Shi Y; Chen Y; Joshi R; Wang Z; Yuan K; Min W
Front Immunol; 2020; 11():968. PubMed ID: 32582152
[No Abstract] [Full Text] [Related]
18. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
19. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
